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Abstract
Background: Atherothrombotic diseases such as myocardial or cerebral infarction are serious
consequences of the thrombus formed in blood vessels. Thrombolytic agents are used to dissolve
the already formed clots in the blood vessels; however, these drugs have certain limitations which
cause serious and sometimes fatal consequences. Herbal preparations have been used since ancient
times for the treatment of several diseases. Herbs and their components possessing antithrombotic
activity have been reported before; however, herbs that could be used for thrombolysis has not
been reported so far. This study's aim was to investigate whether herbal preparations (aqueous
extract) possess thrombolytic activity or not.
Methods: An in vitro thrombolytic model was used to check the clot lysis effect of six aqueous
herbal extracts viz., Tinospora cordifolia, Rubia cordifolia, Hemidesmus indicus, Glycyrrhiza glabra Linn,
Fagonia Arabica and Bacopa monnieri Linn along with Streptokinase as a positive control and water
as a negative control.
Results: Using an in vitro thrombolytic model, Tinospora cordifolia, Rubia cordifolia, Hemidesmus
indicus, Glycyrrhiza glabra Linn, Fagonia Arabica and Bacopa monnieri Linn showed 19.3%, 14.5%,
20.3%, 17.8%, 75.6% and 41.8% clot lysis respectively . Among the herbs studied Fagonia arabica
showed significant % of clot lysis (75.6%) with reference to Streptokinase (86.2%).
Conclusion: Through our study it was found that Dhamasa possesses thrombolytic properties
that could lyse blood clots in vitro; however, in vivo clot dissolving properties and active
component(s) of Dhamasa for clot lysis are yet to be discovered. Once found Dhamasa could be
incorporated as a thrombolytic agent for the improvement of patients suffering from
Atherothrombotic diseases.
Background
A blood clot (thrombus) developed in the circulatory sys-
tem due to failure of hemostasis causes vascular blockage
and while recovering leads to serious consequences in
atherothrombotic diseases such as myocardial or cerebral
infarction, at times leading to death [1]. Thrombolytic
agents that include tissue plasminogen activator (t-PA),
Urokinase (UK), streptokinase (SK) etc. are used all over
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the world for the treatment of these diseases. In India,
though SK and UK are widely used due to lower cost, [2,3]
as compared to other thrombolytic drugs, their use is asso-
ciated with hyper risk of hemorrhage [4] severe anaphy-
lactic reaction and lacks specificity. Moreover, as a result
of immunogenicity multiple treatments with SK in a given
patient are restricted [5]. Because of the shortcomings of
the available thrombolytic drugs, attempts are underway
to develop improved recombinant variants of these drugs
[6-10].
Herbal products are often perceived as safe because they
are "natural" [11]. In India, in recent years, there is
increased research on traditional ayurvedic herbal medi-
cines on the basis of their known effectiveness in the treat-
ment of ailments for which they have been traditionally
applied.
Considerable efforts have been directed towards the dis-
covery and development of natural products from various
plant and animal sources which have antiplatelet [12,13],
anticoagulant [14,15], antithrombotic [16], and throm-
bolytic activity. Epidemiologic studies have provided evi-
dence that foods with experimentally proved
antithrombotic effect could reduce risk of thrombosis.
Herbs showing thrombolytic activity have been studied
and some significant observations have been reported
[17].
The aim of present study was to screen aqueous extracts of
various herbs viz., Tinospora cordifolia (Guduchi), Rubia
cordifolia (Manjistha), Hemidesmus indicus (Anantmool),
Glycyrrhiza glabra Linn(Yestimadhu),  Fagonia Arabica
(Dhamasa) & Bacopa monnieri Linn (Brahmi) for their clot
lysis property (thrombolytic activity) by using an in-vitro
procedure.
Methods
Streptokinase (SK)
To the commercially available lyophilized SK vial
(Polamin Werk GmbH, Herdecke, Germany) of 15,
00,000 I.U., 5 ml sterile distilled water was added and
mixed properly. This suspension was used as a stock from
which 100 μl (30,000 I.U) was used for in vitro thrombol-
ysis.
Specimen
Whole blood (4 ml) was drawn from healthy human vol-
unteers (n = 20) without a history of oral contraceptive or
anticoagulant therapy (using a protocol approved by the
Institutional Ethics Committee of Central India Institute
of Medical Sciences, Nagpur). 500 μl of blood was trans-
ferred to each of the eight previously weighed microcen-
trifuge tubes to form clots.
Herbal preparation
Commercially available total extract of herbs, Tinospora
cordifolia  (guduchi),  Rubia Cordifolia (manjistha),
Hemidesmus indicus (Anantmool), Glycyrrhiza glabra Linn
(yestimadhu)  Fagonia arabica (Dhamasa) and Baccopa
monnieri (Linn) (brahmi) were purchased from Innocon
Foods (Pune, India). The multiple solvent (methanol: iso-
propyl alcohol: acetone) extraction procedure was used to
prepare the extract by the supplier. 100 mg extract was sus-
pended in 10 ml distilled water and the suspension was
shaken vigorously on a vortex mixer. The suspension was
kept overnight and decanted to remove the soluble super-
natant, which was filtered through a 0.22-micron syringe
filter. 100 μl of this aqueous preparation of herbs was
added to the microcentrifuge tubes containing the clots to
check thrombolytic activity.
Clot lysis
Experiments for clot lysis were carried as reported earlier
[18]. In brief, 4 ml venous blood drawn from healthy vol-
unteers was distributed in eight different pre weighed ster-
ile microcentrifuge tube (0.5 ml/tube) and incubated at
37°C for 45 minutes. After clot formation, serum was
completely removed without disturbing the clot and each
tube having clot was again weighed to determine the clot
weight (clot weight = weight of clot containing tube –
weight of tube alone).
To each microcentrifuge tube containing pre-weighed
clot, 100 μl of aqueous extract of six herbs (Tinospora cor-
difolia,  Rubia Cordifolia,  Hemidesmus indicus,  Glycyrrhiza
glabra Linn, Fagonia arabica & Bacopa monnieri (Linn)) was
added separately. As a positive control, 100 μl of SK and
as a negative non thrombolytic control, 100 μl of distilled
water were separately added to the control tubes num-
bered. All the tubes were then incubated at 37°C for 90
minutes and observed for clot lysis. After incubation, fluid
released was removed and tubes were again weighed to
observe the difference in weight after clot disruption. Dif-
ference obtained in weight taken before and after clot lysis
was expressed as percentage of clot lysis. The experiment
was repeated 20 times with the blood samples of 20 vol-
unteers.
Statistical analysis
The significance between % clot lysis by Streptokinase and
herbal extract by means of weight difference was tested by
the paired t-test analysis. Data are expressed as mean ±
standard deviation.
Results
Addition of 100 μl SK, a positive control (30,000 I.U.) to
the clots along with 90 minutes of incubation at 37°C,
showed 86.2% clot lysis. Clots when treated with 100 μl
sterile distilled water (negative control) showed only neg-BMC Complementary and Alternative Medicine 2007, 7:36 http://www.biomedcentral.com/1472-6882/7/36
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ligible clot lysis (4.7%). The mean difference in clot lysis
percentage between positive and negative control was very
significant (p value < 0.0009). After treatment of clots
with 100 μl of Tinospora cordifolia, Rubia cordifolia,
Hemidesmus indicus, Glycyrrhiza glabra Linn, negligible clot
lysis i.e., 19.3%, 14.5%, 20.3%, 17.8% respectively was
obtained but mean of percentage of clot lysis was more
than water. But when 100 μl Fagonia arabica and Bacopa
monnieri were added to two different clots, 75.6% and
41.8% clot lysis was obtained respectively and when com-
pared with the negative control (water) the mean clot lysis
% difference was significant (p value < 0.0001 & = 0.0023
respectively). Percent clot lysis obtained after treating
clots with different herbs and appropriate controls is
shown in Figure 1. Statistical representation of the effec-
tive clot lysis percentage by six herbal preparations, posi-
tive thrombolytic control (Streptokinase) and negative
control (sterile distilled water) is tabulated in Table 1.
Discussion
Herbal preparations are used since ancient times to main-
tain health and regain healthy state of mind. Advances in
phytochemistry and identification of plant compounds,
which are effective in curing certain diseases have renewed
the interest in herbal medicines. About 30% of the phar-
maceuticals are prepared from plants worldwide [19]. A
number of studies have been conducted by various
researchers to find out the herbs and natural food sources
and their supplements having antithrombotic (anticoagu-
lant and antiplatelet) effect and there is evidence that con-
suming such food leads to prevention of coronary events
and stroke [20-23]. There are several thrombolytic drugs
obtained from various sources. Some are modified further
with the use of recombinant technology [24] in order to
make these thrombolytic drugs more site specific and
effective. Side effects related to these drugs have been
reported that lead to further complications [25]. Some-
times the patients die due to bleeding and embolism
[24,26-28].
Herbal preparations, if taken in appropriate dose, can lead
to a better option for curing various ailments. Toxicity of
plant extract is a major concern of scientists and medical
practitioners. Among several methods lethality test has
Clot lysis by Streptokinase, water and various herbal preparations. Figure 1
Clot lysis by Streptokinase, water and various herbal preparations. Effects of drugs on dissolution of clots prepared 
from blood of normal individuals. Maximum clot lysis was observed in clot treated with streptokinase (SK). Among herbal 
drugs Fagonia arabica (Dhamasa) showed 75.6% clot lysis. Bacopa monnieri Linn (Brahmi) showed 41.8% clot lysis. Water (as a 
negative control) showed 4.7% clot lysis. With other herbs negligible clot lysis was observed.
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been successfully used to biomonitor the isolation of
cytotoxic, antimalarial, insecticidal and antifeedants com-
pounds from plant extracts [29]. In this aspect toxicity of
plant extract could be beneficial to mankind however, if
taken in higher/lethal dose plant extracts could be harm-
ful [30,31]. Several lethality tests have been designed and
one such method is the lethality test wherein Brine
Shrimp Lethality (LC50, 24 hr.) test has been used to
determine cytotoxicity which has shown toxicity of Fago-
nia arabica to be 900 μg/ml [29].
In our study of thrombolysis we have tried six herbal prep-
arations that are used since ancient times for neuroprotec-
tion and for curing vascular diseases (Table 2). For
example, Hemidesmus indicus was reported to have anti-
thrombotic activity [32]. The roots of Rubia cordifolia are
used internally in the treatment of abnormal uterine
bleeding, as well as for internal and external haemorrhage
[33]. Bacopa monnieri Linn is used for the treatment of
stroke and Alzheimer disease [34]. Glycyrrhiza glabra Linn
was reported to have antiplatelet and anti-inflammatory
activity [35]. Fagonia arabica is known to have blood puri-
fying property [36]. Tinospora cordifolia along with Fagonia
arabica and Rubia cordifolia was reported to exert neuro-
protection [37]. The aim of this study was to check if these
herbal preparations posses clot lytic activity.
SK, a known thrombolytic drug [38] is used as a positive
control. Water, on the other hand, was selected as a nega-
tive control. The comparison of positive control with neg-
ative control clearly demonstrated that clot dissolution
does not occur when water was added to the clot. The per-
centage of clot lysis by both these controls differ signifi-
cantly as the p value was 0.0009 (test was extremely
significant). Encouraged by the results obtained through
the clot lysis activity by SK and with water as a negative
control we tried six herbal preparations in the same man-
ner. When compared with the clot lysis percentage
obtained through water (negative control), a significant
thrombolytic activity was observed after treating the clots
with Fagonia arabica extract (75.6%; p value < 0.0001).
Fagonia arabica belongs to Zygophyllaceae family [39] and
is known as 'Kharasan' thorn in English and by a common
name of "Dhamasa" in India. It is a green shrub of 1 to 3
feet height, found on calcareous rocks distributed
throughout the Mediterranean region of South Africa,
Afghanistan, India (Rajasthan, northwest Punjab, and
Western India), and Pakistan (Sindh, Punjab, North-West
Frontier Province, NWFP) [40]. The whole plant is used
for medical purpose; popularly known in hilly areas as a
fever remedy source. Infusion is effective as cooling agent
in stomatitis. It is known to purify blood and also acts as
a deobstruent [36]. It is also used for skin diseases, small
pox and for endothermic reaction in the body [41]. The
twigs of the plant are used as remedy for snake bite and
also applied externally as paste on tumors and for the
swellings of neck [39-41].
Interestingly Bacopa monnieri Linn exhibited nearly 50% of
clot lysis. So far, researchers have reported the use of nitric
oxide from Bacopa monnieri Linn in the treatment of stroke
and Alzheimer's sufferers. Moreover, it has been valued as
a cardiac, nerve and brain tonic [34].
There are few plant extracts/products which have been
identified to have fibrinolytic activity. These are Lumbricus
rubellus  [42],  Pleurotus ostreatus [43],  Spirodela polyrhiza
[44], Flammulina velutipes [45], and Ganoderma lucidum
[46], Ginger (Zingiber officinale) [47], Garlic (Allium sati-
vum) [48], Saffron {Crocus sativus Linn (indraceae)} [49]
as well as from Bacillus sp. in Korean and Japanese fer-
mented foods, chungkook-jang [50] and natto [51,52]
respectively. Most of these are enzymes which closely
resembles serine proteases like plasmin as these are rela-
tively specific to fibrin or fibrinogen as a protein substrate.
In general, blood clots are formed from fibrinogen by
Table 1: Effect of six different herbal extracts (10 mg/ml) on in 
vitro clot lysis.
Herbs/Drugs Mean ± S.D. 
(Clot lysis %)
P value when compared to 
negative control (water)
Streptokinase 86.2 ± 10.7 < 0.0009
Fagonia arabica 75.6 ± 2.7 < 0.0001
Tinospora cordifolia 19.3 ± 3.4 0.0045
Rubia cordifolia 14.5 ± 3 0.0231
Hemidesmus indicus 20.3 ± 5.7 0.0072
Glycyrrhiza glabra Linn 17.8 ± 3.4 0.0115
Bacopa monnieri 41.8 ± 6.8 0.0023
Statistical representation of the effective clot lysis percentage by six 
herbal preparations, positive thrombolytic control (Streptokinase) and 
negative control (sterile distilled water) done by paired t-test analysis; 
clot lysis % is represented as mean ± S.D. and a p value < 0.05 was 
considered as significant.
Table 2: List of herbal preparations used in the study and related 
medicinal uses.
S. No. Herbal preparation Medicinal use
1 Fagonia arabica blood purifier, deobstruent
2 Bacopa monnieri treatment of stroke and Alzheimer 
disease
3 Tinospora cordifolia neuroprotection
4 Hemidesmus indicus antithrombotic activity
5 Glycyrrhiza glabra Linn antiplatelet and anti-inflammatory 
activity
6 Rubia cordifolia used internally in the treatment of 
abnormal uterine bleeding, as well 
as for internal and external 
haemorrhageBMC Complementary and Alternative Medicine 2007, 7:36 http://www.biomedcentral.com/1472-6882/7/36
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thrombin and are lysed by plasmin, which is activated
from plasminogen by a tissue plasminogen activator.
However, there is one marine brown algae product called
Seanol (phlorotannin – active compound), have a unique
property in promotion of dissolution of intravascular
blood clot via antiplasmin inhibition [53].
Fagonia arabica is known to have antibacterial activity [29]
which is done against two strains of bacteria notably,
Escherichia coli and Staphylococcus aureus [54]. However,
there are reports of bacterial contaminants of plants
which have plasminogen receptors that bind plasmino-
gen. Cell surface bound plasminogen is easily activated to
plasmin, which could lead to fibrinolysis [55]. Bacterial
plasminogen activator: staphylokinase, streptokinase, act
as cofactor molecules that contribute to exosite formation
and enhance the substrate presentation to the enzyme.
Staphylokinase activates plasminogen to dissolve clots,
also destroys the ECM and fibrin fibers that hold cells
together [56,57].
In context of the above discussion it would be interesting
to investigate the causative components/mechanism for
clot lysis by Fagonia arabica and  Bacopa monnieri Linn
extract with respect to its toxicity, bacterial contamina-
tion, plasmin activation, inhibitors of antiplasmins, or
phytochemicals/secondary metabolites.
Conclusion
In conclusion, on the basis of beneficial effect of Fagonia
arabica (Dhamasa) in the literature and our own results of
the experiments in the extract of same herb, Fagonia ara-
bica lyses blood clots in vitro; however, in vivo clot dis-
solving property and active component(s) of Dhamasa for
clot lysis are yet to be found out. Once found Dhamasa
may be incorporated as a thrombolytic agent for the
improvement of the patients suffering from Atherothrom-
botic diseases.
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